For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .
The efficacy of sildenafil for the treatment of erectile dysfunction in male peritoneal dialysis patients.
BACKGROUND The aim of this study was to evaluate the safety and effectiveness of sildenafil in male peritoneal dialysis patients with erectile dysfunction . METHODS Sixteen peritoneal dialysis patients were recruited to this prospect i ve , r and omized , double-blind , placebo-controlled , crossover study of sildenafil during a period of 8 weeks . Efficacy was assessed by using the International Index of Erectile Function and a Global Assessment Question . Penile arterial supply was assessed by means of Doppler ultrasound in all patients , and adverse events were recorded . RESULTS Three patients failed to complete the study ( 1 patient received a renal transplant , 1 patient died unrelated to the study , and 1 patient withdrew for personal reasons ) . In the remainder , there was a significant improvement in erectile function with sildenafil compared with placebo ( P = 0.01 ) and the baseline assessment ( P = 0.002 ) . There were also significant improvements in intercourse satisfaction ( P = 0.002 ) and overall satisfaction ( P = 0.005 ) compared with baseline . In response to the Global Assessment Question , 75 % of patients reported improvement in erections . Only 1 adverse event was reported : a headache , which resolved after the third dose of sildenafil . CONCLUSION Sildenafil caused a significant improvement in erectile function in peritoneal dialysis patients , with a success rate at least as high as that reported in other patient groups . The drug was well tolerated , with few adverse events
For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .